Inactivation of cancer stem cells (CSCs) is of utmost importance for tumor cure after radiotherapy. An increasing body of evidence complies with a higher radioresistance of CSCs compared to the mass of tumor cells, supporting the use of CSC related biomarkers for prediction of radiotherapy outcome. Treatment individualization strategies for patient groups with vastly different risk of recurrence will most likely require application of more than one biomarker. Specifically, inclusion of established biomarkers like tumor size for primary radio(chemo)therapy or human papilloma virus (HPV) infection status in head and neck squamous cell carcinoma seems to be of very high relevance. The high heterogeneity of CSC subclones along with changes of the functional behavior of individual tumors under treatment underlines the importance of the selection of the optimal timepoint(s) of biomarker evaluation, but also provides a potential therapeutic target for combined treatment approaches with irradiation.
Introduction
Cancer stem cells (CSCs) play a pivotal role in tumor development, progression and recurrence after treatment. CSCs are defined as tumor cells that have an unlimited potential of cell division and an ability to repopulate the whole tumor [1] . For radiotherapy as well as for other potentially curative anti-cancer treatments, this definition implies that all CSCs need to be inactivated in order to permanently eradicate a tumor. The long established gold standard assay to determine CSCs is a functional assay, i.e. the tumor cell transplantation assay measuring the cell number needed to be injected to cause tumor takes in 50% (TD50) of the experimental animals. Technological advances allow us to identify and sort tumor cells for CSC-rich and CSC-low subpopulations, e.g. by cell surface marker expression. Such markers can in many cases also be identified by using staining techniques in tumor sections or by gene expression arrays, ensuring clinical applicability of such parameters for biomarker assays. However, limitations occur from the fact that threshold values for staining intensity cannot be determined by direct validation of the stemness of the stained tumors cells and from the general fact applying to all CSC marker assays, that the marker expression is not specific to CSCs but just determines cells that have a higher likelihood to express CSC features. Thus, stemness of cells has still to be validated by the functional assays mentioned above [2, 3] .
Because of their importance for tumor curability, CSCs can be utilized for strategies to optimize anti-cancer treatments by their evaluation as markers for patient stratification to specific intensified or de-escalated treatment strategies and/or by developing treatment approaches that specifically target tumor cells expressing putative CSC markers.
Radioresistance determined by cancer stem cells
If other confounding factors are constant, the radiation dose to eradicate a tumor inversely correlates with the logarithm of the number of CSCs, i.e. at the same radiotherapy dose tumors with a lower number of CSCs show higher local control rates compared with tumors with higher numbers of CSCs. In experimental and clinical data, this leads to a tumor volume dependence of the curability of tumors, because the absolute number of CSCs is expected to increase with tumor volume [2] [3] [4] [5] [6] . However, also densities of CSCs can differ between tumors, again impacting local tumor control after radiotherapy [6, 7] . The dependence of local tumor control from the number of CSCs contained in a tumor is underlined by the log-linear correlation between the TD50 and the radiation dose necessary to permanently cure 50% of the tumors (tumor control dose 50%, TCD50) [3, 8] . This correlation indicates that, even though CSCs seem to express a constant plasticity, TCD50 is a valuable correlate of the number of CSCs in a given tumor. Nevertheless, some of the described tumor models with equal TD50 show significant discordance in TCD50 values, suggesting that in addition to the total number of CSCs in a given tumor, the inherent radiosensitivity of CSCs as well as other radiobiological parameters may impact local tumor control after irradiation [2, 8] . Such differences of intrinsic radiosensitivity between colony-forming cells in vitro (clonogenic cells) of tumors with the same histology have been shown by the variation of the surviving fraction at 2 Gy (SF2) in colony-forming in vitro assays, which in some studies correlate with clinically observed differences in radiosensitivity between tumor entities or within the same histology [3, 9, 10] . The same correlation between radiosensitivity of clonogenic cells in vitro and tumor radiocurability in vivo exists for tumors of different histologies [11] [12] [13] [14] , supporting a correlation between clonogenicity in vitro and stemness in vivo and the importance of intrinsic radiosensitivity of CSCs for radiocurability of tumors. Of note, such preclinical data on established tumor models are of high importance for our today's understanding of the biology of CSC, however, specific questions especially concerning detailed gene expressions or tumor to normal tissue interactions may in many cases require the use of primary xenografts. It is not the scope of this review to discuss the use of different experimental models in detail.
Taking into account that tumors can potentially arise from a single CSC, a failure of radiation treatment might be attributed to the incomplete eradication of the entire CSC population [3, 15] . The cure rate of irradiation results from its ability to induce DNA damage in tumor tissue through production of the water-derived reactive oxygen species or by direct ionization of the DNA molecules [16] . At the cellular level, DNA damage has long and short term consequences. An acute effect is related to the disturbance of DNA metabolism such as DNA replication and RNA transcription. Based on the status of DNA repair and the nature of the DNA lesions, the outcome of DNA injury can be temporary or permanent cell arrest, immediate or delayed cell death or mutagenesis of the surviving cells, which in turn might lead to genomic instability and subsequently results in tumor development in a long term perspective [17] .
The biological consequences of irradiation leading to cell death are highly influenced by the activation of the DNA damage response (DDR) mechanisms. Among the various types of DNA damages produced by ionizing irradiation, i.e. single strand breaks (SSBs), double strand breaks (DSBs), damaged nucleotide bases or abasic sites, DSBs represent the principal lesions that might lead to cell death if not adequately repaired [16] . Both normal and tumor cells can repair DSBs by either error-free homology-directed recombination (HR) or errorprone non-homologous end joining (NHEJ) mechanisms which are acting in an overlapping and complementary manner [18] . In addition to the activation of DNA repair process, DNA damage induces checkpoint kinase signaling pathways such as ataxia telangiectasia mutated (ATM)-checkpoint kinase 2 (Chk2) and ATM-Rad3-related (ATR)-checkpoint kinase (Chk1) which delay cell cycle progression in order to allow DNA repair [18] . When DNA damage is beyond the cell repair capacity, proteins of DDR signaling mediate cellular death or loss of reproductive capacity through activation of different pathways such as apoptosis, senescence or mitotic catastrophe [19] . Therefore, the efficacy of the DNA repair machinery activated by the DNA damage signaling network is critical and determines cell death or repair. A high DNA repair capacity has been described for CSC populations in different tumor entities including glioblastoma, prostate, lung and breast cancers and mainly attributed to the activation of the ATR-Chk1 and ATM-Chk2 signaling pathways [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , as summarized in Table 1 .
Radiation-induced cell death occurs not only by a direct energy transfer to the DNA but, in case of conventional photon radiotherapy, mainly as a result of generation of the free radicals, including the chemically reactive products of oxygen metabolism called reactive oxygen species (ROS) [31] . Under physiological conditions, these metabolites are involved in the signaling events regulating different cellular processes such as differentiation, proliferation, autophagy and survival [32] . However, if ROS production is beyond the capacity of the cellular antioxidant system, it may lead to the irreversible oxidative stress and cell death [33] . The physiological ROS level is maintained by the scavenging molecules such as glutathione, dismutase, peroxidase, thioredoxin, catalase, and superoxide [33] . In addition, adverse effect of ROS can be also minimized by an adequate DDR response [34] . A highly efficient ROS scavenging system or generally lower ROS levels in CSC may contribute to the high resistance of CSC populations to genotoxic stress described for different tumor entities [35] [36] [37] [38] (Table 1) .
Besides the above-described intrinsic mechanisms underlying CSC radioresistance, the CSC fate under physiological conditions and during treatment is tightly regulated by a broad range of extrinsic microenvironmental stimuli [39, 40] . Within a tumor, CSCs can reside in specific niches occupying different locations including hypoxic, perivascular and invasive tumor areas that can dynamically change during tumor development and treatment [41, 42] . A CSC niche is defined by various soluble factors, extracellular matrix (ECM) elements and direct cell-cell interactions via cell surface molecules. Depending on oxygen tension, a niche occupied by CSCs may define differentiation, self-renewal and treatment resistance of the CSCs. The CSCs residing in the hypoxic [36] niche can be partly protected from radiation insults compared to normoxic cells through less ROS generation and activation of the hypoxia-inducible factor (HIF) signaling route [43] [44] [45] . The transcription factors HIF-1α and HIF-2α are regulators of the gene transcription at hypoxia response elements (HREs) that activate pro-survival developmental pathways such as Notch, wingless and INT-1 (WNT) and Hedgehog [46] [47] [48] . Activation of these signaling pathways is essential for CSC maintenance and associated with resistance to radiotherapy and accelerated repopulation of CSCs during or after treatment [28, 30, [49] [50] [51] (Table 1) . Another important factor is the epithelial-mesenchymal transition (EMT) as a key process in regulation of tissue development, but also of invasion and metastasis of tumors [52] . In pancreatic cancer, the presence of pancreatic stellate cells has been shown to enhance radioresistance and at the same time to promote EMT and to induce CSC marker expression. Tumor take seemed to be accelerated and potentially enhanced [53] . This link between EMT, CSC and radioresistance, although mechanistically not completely understood, is supported by preclinical in-vitro data on prostate cancer cells [54] and lung cancer [55] . EMT may also cause migration of tumor cells into blood vessels, where they are detectable as circulating tumor cells (CTC) in many cancer patients. The presence of CTC has been associated with an increased risk of tumor recurrence and distant metastases. Features of EMT and CSCs are often evident in CTC and have been shown to be a better predictor of treatment outcome as compared to the sole number of CTC per volume of blood [56, 57] .Overall, an increasing body of evidence supports a higher radioresistance of CSCs compared to the mass of tumor cells. Underlying mechanisms are increasingly but by far not completely unraveled. Open questions include why, if there is a major difference in radioresponse between CSC and non-CSC, CSC-independent biomarkers (see also below) can work at all as prognostic or predictive markers for radiotherapy. Another interesting question is why for radiotherapy alone the response of tumors in terms of growth delay, an endpoint that depends on the mass of tumor cells, fairly correlates with local control (TCD50), which depends on CSCs, whereas for combined radiotherapy and non-CSC-active systemic treatments, strong effects on growth delay are observed with at the same time missing effects on local tumor control [58] . Based on the knowledge that CSCs are inactivated by irradiation, but just seem to require higher doses as compared to non-CSC, it can only be speculated whether the correlation between growth delay and local tumor control could be caused by an existent correlation of CSC radiosensitivity and non-CSC radiosensitivity that is not a 1:1 correlation but includes either a factor or a threshold value.
Cancer stem cells as prognostic or predictive biomarkers in patient tumors
Throughout its history, radiotherapy has taken into consideration individual factors for treatment planning, like patient anatomy, tumor localization, tumor stage or tumor mass. Recent data imply that specific biological characteristics of the tumor are excellent biomarkers that can serve as a basis for studies on further radiotherapy treatment individualization (see below). Putative CSC markers have been evaluated for many cancer types in preclinical and clinical studies. The following section will discuss two tumor entities, i.e. head and neck squamous cell carcinoma (HNSCC) and glioblastoma multiforme (GBM), that have been evaluated frequently for the prognostic or predictive value of CSC markers. For a review of other tumor entities see [59] .
A seminal study on the impact of CSC marker expression and local tumor control after radiotherapy has been published several years ago: In patients with early laryngeal cancer treated by primary radiotherapy with curative intention, gene expression profiling has been performed retrospectively in the tumor material in order to identify biomarkers that could predict tumor recurrence after radiotherapy. Patients with subsequent tumor recurrences were matched for other relevant parameters like T-stage, subsite, treatment, gender and patient age with patients who did not develop tumor recurrences. The authors generated whole genome gene expression data on the pre-therapeutic biopsies from 52 patients followed by immunohistochemical analysis in a validation cohort of 76 patients and demonstrated that CD44 mRNA and protein expression significantly correlates with the risk of tumor recurrence [60] . CD44 is a transmembrane glycoprotein receptor interacting with a wide variety of the ECM ligands including hyaluronan (HA), collagen, laminin, fibronectin and osteopontin [61] . Although the mechanisms of regulation of tumor radioresistance by CD44 are not clear yet, a few in vitro studies demonstrated that CD44 can interplay with epidermal growth factor receptor (EGFR) and activate c-Met, focal adhesion kinase (FAK) and AKT signaling pathways and contributes to ROS defense by upregulation of reduced glutathione [62, 63] , which in turn might lead to an increase of cell radioresistance [64] [65] [66] . Interestingly, in accompanying in-vitro experiments using different laryngeal cancer cell lines, plating efficiency but not radiosensitivity correlated with CD44 expression [60] . Although plating efficiency is a measure for clonogenicity of tumor cells, it does not always correlate with tumorigenic properties. In addition, in vitro cell growth conditions might not properly reflect a native tumor microenvironment including oxygen tension, pH, growth factors and interaction with ECM proteins which serve as CD44 ligands. Furthermore, the established cancer cell lines cultured in vitro for decades possess multiple genetic alterations and might very roughly resemble primary tumor cells. Therefore, the data obtained with the common cell lines need to be interpreted with caution [67] . Thus, although the data support that CD44 is a measure for density of CSC rather than for their intrinsic radiosensitivity, the question about putative intrinsic radioresistance of CD44 HNSCC cells remains open and warrants further in vivo investigations [7] . Both density and intrinsic radiosensitivity of CSC correlate with local tumor control probability after radiotherapy [7] and it has been shown in experimental datasets in vivo that in tumors with the same histology both parameters can be attributed to the intratumoral heterogeneity of local tumor control probabilities after clinically relevant fractionated irradiation [6] .
In line with these findings, recent multicenter studies of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) revealed a significant association of the expression of putative CSC markers with locoregional tumor control after radiochemotherapy of HNSCC both in the primary [Baumann, Linge, Lohaus et al., unpublished] as well in the postoperative setting [Linge et al. under revision]. In the latter study CD44, hepatocyte growth factor receptor (HGFR, also called MET) and solute carrier family 3A2 (SLC3A2) expression in the surgical specimen correlated with locoregional tumor recurrence, and in case of MET and SLC3A2 also with distant metastases in human papillomavirus (HPV) negative HNSCC patients after surgery and postoperative radiochemotherapy [Linge et al., under revision]. This is of special interest as postoperative radiochemotherapy is applied in order to inactivate potentially remaining very low numbers of tumor cells. In such datasets, some patients may already have been cured by surgery alone, i.e. they had no remaining tumor cells, which would be expected to weaken prognostic or predictive values of all biomarkers that are thought to measure sensitivity to postoperative treatments. The observation of a significant association between CSC markers and outcome of radiotherapy after surgical removal of the tumor indicates that the number of CSC remaining in the tumor bed or in the neck after surgery is high for tumors with high CSC density compared to tumors with low CSC density. Whether the mechanism is merely statistical, i.e. a higher proportion of an otherwise similar number of tumor cells remaining after surgery is CSC, or whether high CSC density tumors also show higher infiltrative potential or metastatic escape via lymphatics is currently unknown and warrants further investigation.
Another putative CSC marker for HNSCC is 26S proteasome activity, a multicatalytic protease complex with regulatory functions in cell cycle, DNA repair and cell survival [68] . As demonstrated in a clinical-preclinical dataset, in different HNSCC cell lines a low 26S proteasome activity correlated with a higher self-renewal capacity and a higher tumorigenicity of the cell lines. In line with these experimental data, patients who underwent primary radiochemotherapy for HNSCC had a longer survival and higher locoregional tumor control rates if their tumors showed a high 26S proteasome activity [69] .
Another example with a substantial number of clinical datasets is GBM. GBM belong to the tumor entities that are most resistant to radio(chemo)therapy and to other forms of cancer treatment. There is presently no chance of permanent tumor control. Radioresistance of GBM can be partly explained by a comparably high intrinsic radioresistance of clonogenic GBM cells [70] and thus likely also of GBM-CSC. On the other hand, specifically more radio(chemo)therapysensitive GBM, i.e. with hypermethylation of O-6-methylguanine-DNA methyltransferase (MGMT) promotor, show higher frequencies of recurrences outside the radiotherapy treatment volume compared to MGMT non-methylated tumors [71] , implying a high mobility of tumor cells or multifocal tumor growth. MGMT removes temozolomide (TMZ)-generated O6-methylguanine and thereby supports DNA repair. Therefore, MGMT inactivation through promoter methylation is associated with a high sensitivity to TMZ treatment [72] .
Glioma-initiating cells might originate from neural stem cells and lineage restricted progenitor cells [73] and GBM stem cells are believed to reside in the stem cell niche in the subventricular zones [74] . GBM initial lesions with contact to the cortex and the subventricular zone have been shown to recur frequently multifocally and outside of the original treatment volume [75] . Although controversial [76] , high radiation doses to the subventricular zone may increase patient survival [77] [78] [79] . This effect may be explained by a slow-down of proliferation of precursor cells [80] . A putative CSC marker that has been intensively investigated in a number of human cancers including glioma is the membrane glycoprotein CD133 [81] and it has been suggested that CD133 positive glioma CSCs are more resistant to drug treatment [82] and to radiotherapy [23] compared to CD133 negative cells. However clinical data on the prognostic value of CD133 expression in GBM remain controversial. The first study providing evidence for a correlation of higher stem cell content with worse outcome in GBM was a posthoc evaluation of tumor material collected within the phase II and randomized phase III trials on adjuvant radiotherapy with or without temozolomide [83, 84] . Here, expression of HOX genes that play an important role in the developmental processes, status of MGMT methylation and high expression of the epidermal growth factor receptor (EGFR) correlated with lower survival. The HOX gene set comprises CD133 and was prognostic only for survival after postoperative radiochemotherapy but not after radiotherapy [85] . The association of HOX gene expression with survival was validated in a second cohort of patients from the same trials, thus increasing the reliability of the dataset. The data are in line with later publications showing a correlation of higher CD133 protein expression [86, 87] or gene expression [88] with poor overall and progression free survival after postoperative radiochemotherapy. In contrast to these data, in a prospective study on 61 consecutive patients receiving complete or partial surgical resection of their GBM and adjuvant radiochemotherapy, in addition to patient related factors, MGMT hypermethylation and high CD133 mRNA expression correlated with better progression free and overall survival [89] . No significant association of CD133 protein expression and survival after radiochemotherapy was found in another study using immunohistochemical techniques [90, 91] . Interestingly, CD133 expression has been shown to be higher in tumor recurrences compared to the initial tumor. This increase could be explained by both CSC and non-cancer neural stem cells and was associated with a longer survival [86] . Thus, tumor recurrences have to be treated as a separate cohort for the evaluation of biomarkers. The contradictory data for the prognostic relevance of CD133 in the primary treatment situation of GBM may in parts be explained by inhomogeneous patient cohorts in some of the datasets, by different location of the tumors with different likelihood of out-off field recurrence, by different techniques used for quantification of CD133 and by the setting of different threshold values for immunohistochemical techniques to name only few. Overall, the data contradict the use of CD133 as a sole marker for treatment individualization studies in GBM.
Importance of further biomarkers for patient stratification
The aim of a biology based patient stratification for future treatment individualization trials must be to identify patient groups whose chance of tumor cure after current standard treatment is approaching 100% and/or patient groups with poor tumor control rates. Such patient groups can then be brought into treatment de-escalation or treatment intensification trials, respectively. In contrast, for patients between these extremes it is currently extremely difficult to design a personalized interventional strategy which can be tested in clinical trials without major risk to reduce their individual chance of uncomplicated tumor control. For these patients, traditional clinical trials, accompanied by translational studies into refined biomarker panels, appear currently as the best strategy. The definition of extremely good or very poor prognosis group very likely requires the application of several biomarkers, where CSC markers are only one of them.
For primary radio(chemo)therapy, tumor size is an established biomarker that needs to be included as a relevant parameter into all studies for patient stratification for individualized radiotherapy. In a re-evaluation of clinical data on different tumor entities from the literature, a sigmoid negative tumor volume-response curve could be established. This curve correlated well with the curve predicted from radiobiological knowledge, but the predicted curve was overall steeper than the curve adapted for the clinical data. The predicted curve assumed that on average, the number of clonogens (here CSC) is increasing linearly with tumor volume and that all other biological factors are comparable between small and large tumors [4] . The strong correlation of tumor volume and local tumor control after radiotherapy has been supported by a number of clinical datasets [92, 93] [Lohaus et al., DKTK, unpublished] . There is even evidence that the efficacy of different fractionation schedules of radiotherapy depends on the tumor volume at the start of radiotherapy [94] . Along with inaccuracies of tumor volume measurement and differences in treatment schedules, the above mentioned more shallow decrease of the clinical curve is likely to be explained by confounding factors that in addition to the number of CSC explain tumor radiosensitivity, such as intrinsic radioresistance or tumor micromilieu parameters like hypoxia [95] . The data show the strong impact of tumor volume or CSC number on local tumor control after radiotherapy, however, they also support the use of additional biomarkers as a basis for patient stratification, as demonstrated also by a prospective evaluation on the impact of tumor volume in lung cancer [96] .
Especially for HNSCC, positivity of the tumor for high-risk subtypes of the human papilloma virus (HPV) has been shown to lead to better survival and locoregional tumor control after primary radio(chemo)-therapy [97, 98] [DKTK data in preparation]. The HPVs are small double-stranded DNA viruses. Their genome encodes eight viral proteins including the two pro-proliferative oncoproteins E6 and E7, which lead to carcinogenesis by inhibition of the p53 and Rb tumor suppressor pathways [99] . Underlying reasons for the higher radiosensitivity of HPV positive HNSCC may be an impaired DNA repair capacity in HPV positive tumor cells [100] and/or higher immunogenic effects of HPV positive tumors [101] . HPV positivity determined by p16 protein expression or by HPV16 DNA positivity is already being widely used as a stratification parameter in prospective clinical trials in HNSCC.
Another important biological parameter is tumor hypoxia. Tumor hypoxia increases tumor cell radioresistance [102] . Local tumor control in experiments in vivo [103] and in patient tumors has been shown to correlate with the extent of hypoxia or surrogate markers of hypoxia [104] [105] [106] [107] . Modification of hypoxia during radiotherapy has a significant positive impact on locoregional tumor control and survival in HNSCC, as shown in clinical trials [108] . The correlation of hypoxia with outcome of radio(chemo)therapy may not only be a consequence of a direct effect of hypoxia on tumor cell radioresistance, but also of a more malignant phenotype and higher intrinsic radioresistance of hypoxic tumors. This is supported by the fact that tumor models with higher hypoxic volume are more radioresistant even if radiotherapy is performed under artificially homogeneously anoxic conditions [6] and by the fact that tumor hypoxia profiles determined with mRNA expression arrays also correlate with local tumor control in postoperative radiochemotherapy, i.e. when the hypoxic primary tumor has been surgically removed [Linge et al., under revision, see below]. Independent of the underlying mechanisms, hypoxia appears to be a valuable biomarker for prediction of radio(chemo)therapy outcome. Clinical studies are today using mostly non-invasive techniques of hypoxia measurement, e.g. by evaluation of gene panels in the surgical specimen or in the tumor biopsy or, if the tumor is still in situ, imaging modalities, most frequently positron emission tomography (PET) with hypoxia-specific tracers like 18 F-misonidazole. These biomarkers have been demonstrated to correlate with locoregional tumor control after primary radiochemotherapy in HNSCC [106, 107, [109] [110] [111] [112] [113] . Although there is an interaction of hypoxia and CSC with CSC being able to sustain stem cell capabilities under hypoxic more than under oxic conditions, both parameters cannot be subsumed under the same biomarker [43] .
The clinical value of multi-biomarker assays including CSC and hypoxia markers has been demonstrated in the above mentioned multicenter DKTK trial on biomarkers for locoregional tumor control after post-operative radiochemotherapy. After postoperative radiochemotherapy in HNSCC patients, HPV16 DNA positivity led to locoregional tumor control over 5 years was~97% [114] . In the HPV16 DNA negative group, locoregional tumor control over 5 years was~80%, which warrants additional biomarkers to further stratify this subgroup into additional patients with favorable outcome and patients with very low chance of locoregional tumor control. In additional analyses, hypoxia gene panels and CSC markers have been evaluated. Indeed, patients with HPV16 DNA negative tumors, high CSC marker expression (MET or SLC3A2) and high hypoxia gene expression within the surgical specimen showed much lower locoregional tumor control rates with~65%. On the other hand, low CD44 expression in HPV16 DNA negative tumors identified additional patients who belong to the advantageous group with~100% locoregional tumor control (Linge et al., under revision). Further biomarker evaluations are underway in order to find the most promising parameters that can be used for later treatment individualization studies.
Even though radiotherapy is a locoregional treatment, it is important to also include biomarkers with predictive potential for distant metastases into panels that serve as a basis for treatment individualization. It is, for example, not rational to increase the aggressiveness of locoregional treatments at the risk of higher side effects, if for an individual patient the risk of distant metastases is very high. Cancer stem cell markers may serve as both, markers for locoregional control and for distant metastases. Within the DKTK study, high MET and SLC3A2 expression was also associated with 3-4 times higher rates of distant metastases. However, it has been shown preclinically that stem cell potential per se does not necessarily increase metastatic potential [115] , thus specific biomarkers for metastatic CSC may help to increase the sensitivity of such tests. In the above referenced article, microRNA-9 (miR-9) was shown to distinguish between these two types of CSC. However, clinical data on this topic are widely missing so far. Further refinement of biomarker evaluations will in future have the potential to select patient groups which, due to their high risk of distant metastases, need additional systemic treatment or which would even be candidates for omission of intense local treatment.
Overall, the inclusion of established biomarkers together with molecular or genetic testing for e.g. CSC marker profiles or other markers of radioresistance will allow patient stratification into subgroups with considerably different radioresistance that can in future serve as a basis for treatment individualization. Higher stratification into more subgroups leads at the same time to lower heterogeneity within the patient groups and thus to a steeper radiation dose-response relationship (Fig. 1) . As a consequence, treatment intensification e.g. by radiation dose escalation would be expected to lead to a comparably higher increase in tumor control as compared to the same intensification applied to the whole patient group or to lesser stratified subgroups.
Intratumoral heterogeneity and changes of biomarker profiles during treatment
Tumor cell heterogeneity is attributed to the continued genetic and epigenetic changes occurring within an individual clonogenic cell and selected during somatic evolution, which might have a multidirectional nature due to the spatial intratumoral diversity in the oxygen tension, pH, nutrient supply, growth factor availability as well as the cell content within CSC niche. Intratumoral heterogeneity can lead to treatment resistance due to a wide variation of the response of different subpopulations [116] . As demonstrated recently for example in renal cell carcinoma, the majority of all somatic mutations detected by exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple a) Whole Patient population b) Stratification with 1 biomarker c) Stratification with more biomarkers Fig. 1 . Theoretical sketch of the potential value of multiple biomarker testing of a patient group with the same tumor and, according to today's treatment standard the same treatment strategies. a) The whole patient population has a certain dose response relationship, which, due to the heterogeneity between the different individual tumors, is relatively shallow. b) Using one biomarker, e.g. a CSC marker, the whole population may be separated into two distinct groups with different tumor radiosensitivity. The heterogeneity between the groups gets lower, thus the radiation dose -response relationships get steeper. c) The application of more biomarkers may allow the definition of more distinct patient groups with still considerably different radiosensitivity. The steepness of the dose-response relationships gets again higher, because the heterogeneity between the patients in one group is again reduced. Such strategies lead to the fact that e.g. radiation dose escalation in the patient groups with worse prognosis leads to higher increase in local tumor control as compared to the same approach applied to the whole patient population.
spatially separated samples within primary tumors and their metastases, was not present in all investigated tumor regions [117] . The study of Kreso and co-workers demonstrated that not only genetic variety, but also epigenetic changes might contribute to cancer growth and therapy tolerance. This study employed DNA copy number alteration profiling, deep sequencing and in vivo tracking of 150 single lineages derived from 10 human colorectal cancers. These lineages were characterized for their genetic pattern and repopulation dynamics after treatment with oxaliplatin [118] . Using serial transplantation experiments, a dynamic regulation of CSC clones could be shown in these human colorectal cancer cell lines [118] , while genomic profiles of the primary human tumor sample retained the same overall serially passaged xenografts, the repopulation dynamics of distinct tumor subclones was heterogeneous with stability of some clones and transient detectability of other clones. Distinct subclones increased over time, most likely due to initial dormancy of the cells, others disappeared and re-appeared later again. Along with these clonal changes, chemotherapy tolerance was different between the different genetically identical subclones [118] . In addition to the genetic and epigenetic variety, tumor microenvironment also contributes to the functional diversity and evolution of cancer cells, e.g. hypoxia and inflammation might induce EMT and associated epigenetic changes, and the presence of hypoxia was associated with chromosomal instability [43, 119, 120] . Furthermore, different microenvironmental stimuli in vivo such as hypoxic conditions, anticancer therapy or defined genetic alterations can trigger epithelial to mesenchymal transition and induce reprogramming of the differentiated tumor cells into induced CSC populations [121] [122] [123] , thereby affecting radioresistance. This may apply for heterogeneity within one tumor, but also for changes under treatment. Therefore, resolving CSC heterogeneity during the course of treatment might be essential for the development of biomarkers that reflect individual prognosis and predict clinical outcome. Due to the palliative nature of chemotherapy alone in solid tumors, this factor may be more relevant to chemotherapy than to radiotherapy or surgery.
In preclinical experiments on prostate cancer cells, radiotherapy led to upregulation of CSC markers and differentially regulated pathways (aldehyde dehydrogenase (ALDH) activity, OCT4, NANOG, BMI1, ATP-binding cassette sub-family G member 2 (ABCG2), phosphatidylinositide 3-kinases PI3K/AKT pathway activation, increased β-catenin and vimentin expression as marker for EMT) [28] [Peitzsch et al., under revision] . At the same time, a phenotypic switch during radiotherapy could be demonstrated by the presence of the active histone methylation marks at the promoter sequence of ALDH1A1 gene and, as a consequence, a higher tumorigenicity and radioresistance of the prostate cancer cells that underwent multiple irradiations. Interestingly and translationally highly relevant, this histone methylation could be abrogated by treatment with the methyltransferase inhibitor DZNep, leading at the same time to an inhibition of tumorigenicity and radioresistance [Peitzsch et al., under revision] . Similar variabilities of putative CSC markers during radiotherapy have been shown for ALDH1A3 expression in HNSCC, where an increase of the expression after irradiation by either induction or selection correlates with in vivo tumor radiocurability [124] . Besides a higher radioresistance of CSCs compared to non-CSC tumor cells, such effects can be explained by a generation of new CSCs from previously non-tumorigenic cells after irradiation [123, 125] , potentially as a consequence of pro-inflammatory signaling within normal tissue cells of the tumor microenvironment after irradiation [126] and/or due to hypoxic microenvironmental conditions [127] .
Variability under radiotherapy is also known for other biomarkers, with hypoxia being one of the best evaluated markers. Mechanistically, this is of special interest because interactions with CSC related biomarkers may exist (see also above, CSC niches, Section "Radioresistance determined by cancer stem cells"). In preclinical in-vivo experiments, correlation of the hypoxic volume measured immunohistochemically with pimonidazole was stronger when the biomarker was evaluated after 2 weeks of the 6-week course of radiotherapy compared to a pretreatment evaluation [128] . These data were supported by a subsequent clinical study showing the strongest correlation between hypoxia measured with 18 F-misonidazole PET and locoregional tumor control when hypoxia was evaluated after 2 weeks of radiochemotherapy [107] . A validation study is currently under evaluation [Baumann Abstract 10LBA, ECCO 2015] and a prospective interventional trial is in preparation. Interestingly, not only the size, but also the spatial distribution of hypoxic areas is heterogeneous during the course of radiochemotherapy, a fact that needs to be considered when radiotherapy boost strategies are evaluated for putatively radioresistant hypoxic areas [129] . Another example is the expression of the EGFR before and during radiotherapy, which has been shown to be differentially regulated in different individual tumor models of the same histology under the same radiotherapy treatment schedule [130] .
Overall, an increasing body of evidence supports the variability of biomarkers during treatment together with consequences for the predictive value of the respective marker. These data warrant careful translational investigations with repeated evaluations under treatment using non-invasive or minimally invasive procedures, because the predictive power of specific markers may in some cases also be determined by its dynamics in the early treatment phase. In a translational study, the 3-hydroxy-3-methylglutaryl-coenzyme-A-reductase (HMG CoA reductase) inhibitor simvastatin could be demonstrated to radiosensitize mammosphere-initiating cells of different inflammatory and triple negative breast cancer cell lines. In contrast, radioprotective effects of simvastatin were observed in two other noninflammatory breast cancer cell lines. In a retrospective clinical evaluation of 519 patients with inflammatory breast cancer, the use of statins was one of the factors that showed an independent association with local recurrence free survival [131] . These data support the performance of an early prospective clinical trial for this very-high-risk group of breast cancer patients.
In pre-clinical experiments, an immunoconjugate of an anti-CD44v6 monoclonal antibody and the maytansinoid DM1, was applied during fractionated irradiation in a human HNSCC tumor model. The simultaneous treatment led to a significant improvement of permanent local tumor control by a dose modifying factor of 1.9, which is substantial compared to the majority of other experimental combined treatment approaches [132] . Although the compound is not further pursued by the manufacturer in the context of radiotherapy, these data strongly support the evaluation of similar approaches using targets that have a higher tumor specificity. In line with the before mentioned data, in a clinical-preclinical trial in pancreatic cancer, patients with high tumor expression of the standard isoform of CD44 correlated with significantly shorter overall survival compared to patients with lower expression. In translational-preclinical experiments, anti-CD44 antibodies were applied alone or with radiation. Although there was no radiosensitizing effect of the drug in in-vitro colony formation assays, the drug alone showed significant cytotoxic effects on clonogenic tumor cells, reduced in vitro cell viability and invasion as well as in vivo tumor growth in a volume-based assay along with a down-regulation of stem cell selfrenewal genes Nanog, Sox-2, and Rex-1 [133] .
Another promising avenue is the application of radiolabelled antibodies used as theragnostics, i.e. for diagnosis e.g. with positron emission tomography and, with another radionuclide, as a therapeutic approach. Proof for this strategy has been shown with the radiolabelled anti-EGFR antibody cetuximab that led to significant improvement of local tumor control when applied together with external beam radiotherapy [134] . Such targeting approaches are in principal also possible with other receptors or proteins that are higher expressed in the tumor compared to surrounding normal tissues, including putative CSC specific proteins [135] .
Some early clinical trials that are ongoing or just finished evaluate the applicability and efficacy of e.g. NOTCH or Hedgehog pathway inhibitors together with palliative radiotherapy. It is currently too early to conclude on any of their results. Especially in the context of radiotherapy, research strategies need to focus on combined treatments with drugs that are as specific as possible to CSC with no or only minor effects in surrounding normal tissues in order to avoid an increase of radiogenic toxicities in normal tissues. Another highly important issue is the bioavailability of the drugs to the CSCs, which may be located in hypoxic niches with little or no blood perfusion. This is especially critical if the target of the drug is also expressed on non-CSCs that may be situated closer to the vessel along the diffusion path and/or if the plasma halflife of the drug is short. Such effects may hinder the inactivation of CSCs by the drugs in vivo, even if there is a cytotoxic effect on CSCs in vitro. The problem may be partly eluded by the development of drugs with long plasma half-life and high specificity to CSCs (see above) or by radiopharmaceutical approaches (see above) that use radionuclides with a range that covers also some surrounding cell layers, however, therewith loosing specificity to CSCs.
Conclusion
Overall, current preclinical and clinical findings suggest that CSC density and inherent radioresistance are indicative of tumor radiocurability, underlining the great promise of CSC-related predictive tests for clinical trials on radiotherapy individualization. Nevertheless, there are still some pitfalls that have to be taken into consideration. In particular, an increasing body of evidence supports the use of multiple-variable approaches, where CSC markers may only be one part. Specifically, inclusion of known and long established biomarkers like tumor size for primary radio(chemo)therapy or HPV infection status in HNSCC is essential in order to define patient groups with very different treatment outcome as a basis for clinical trials on radiotherapy treatment individualization. This in turn leads to the necessity of large patient populations to be included into clinical trials, requiring multi-institutional co-operation in order to recruit substantial patient numbers for highly specified subgroups of tumors. In addition, specifically to CSC, a high heterogeneity of different subclones (or reprogramming) within individual tumors has been observed under treatment along with changes of the functional behavior of the tumor, underlining the importance of the selection of the optimal methods and timepoint(s) of biomarker evaluation, but also providing a potential therapeutic target for combined treatment approaches with irradiation. 
